ARTICLE | Clinical News
S: Phase II started
September 1, 2008 7:00 AM UTC
Merck began a double-blind, placebo-controlled Phase II trial in 198 patients with end-stage kidney disease on hemodialysis. The company licensed rights to develop, manufacture and market the vaccine ...